Patients with hidradenitis suppurativa may suffer from neuropathic pain: A Finnish multicenter study - 27/02/20
Doi : 10.1016/j.jaad.2019.11.016
Laura Huilaja, MD, PhD a, ⁎ 
, Mirkka J. Hirvonen, PhD b, Tiina Lipitsä, MD c, Armi Vihervaara, MD d, Rauno Harvima, MD, PhD, DSc c, Harri Sintonen, PhD e, Jukka Pekka Kouri, MD f, Martta Ranta, MSc b, Rafael Pasternack, MD, PhD g
, Mirkka J. Hirvonen, PhD b, Tiina Lipitsä, MD c, Armi Vihervaara, MD d, Rauno Harvima, MD, PhD, DSc c, Harri Sintonen, PhD e, Jukka Pekka Kouri, MD f, Martta Ranta, MSc b, Rafael Pasternack, MD, PhD g a PEDEGO Research Unit, University of Oulu, and the Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, Finland
b AbbVie Oy, Espoo, Finland
c Department of Dermatology, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland
d Department of Dermatology, Turku University Hospital, Finland
e Department of Public Health, University of Helsinki, Helsinki, Finland
f Orton, Helsinki, Finland
g Department of Dermatology, Tampere University Hospital and Tampere University, Tampere, Finland
∗Correspondence to: Laura Huilaja, MD, PhD, Department of Dermatology, University of Oulu, Aapistie 5A, FIN-90029 Oulu, FinlandDepartment of DermatologyUniversity of OuluAapistie 5AOuluFIN-90029Finland
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Thursday 27 February 2020
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
| Funding sources: The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. |
|
| Conflicts of interest: Dr Huilaja has received educational grants from CSL Behring, Shire, Janssen-Cilag, Novartis, AbbVie, and LEO Pharma; honoraria from Novartis, Sanofi Genzyme, and UCB Pharma for consulting and/or speaking; and is an investigator for AbbVie. Dr Lipitsä has received educational grants from AbbVie and is an investigator for AbbVie. Dr Harvima has received educational grants from AbbVie. Dr Vihervaara has received educational grants from AbbVie, Jansen, Novartis, and Celgene. Dr Pasternack has received educational grants from AbbVie, Janssen, LEO Pharma, Novartis, Pfizer, and Sanofi Genzyme; honoraria from AbbVie, Galenica, Eli Lilly, Janssen, Novartis, and Sanofi Genzyme for consulting and/or speaking; participated in clinical studies sponsored by AbbVie, Novartis, Eli Lilly, and Regeneron, and is an investigator for AbbVie. Dr Kouri has received educational grants from Pfizer. Authors Ranta and Hirvonen are employees of AbbVie and may or may not own AbbVie stock. Author Sintonen has no conflicts of interest. |
|
| IRB approval status: The Tampere University Hospital Ethics Committee approved this study (R16017/2016). |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?